წყაროები
ძირითადი სტატიები
Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022 Jul;36(7):1720-48.სრული ტექსტი აბსტრაქტი
Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200-8.სრული ტექსტი აბსტრაქტი
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: acute lymphoblastic leukemia [internet publication].სრული ტექსტი
Hoelzer D, Bassan R, Dombret H, et al. Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep;27(suppl 5):v69-82.სრული ტექსტი აბსტრაქტი
გამოყენებული სტატიები
1. Pui CH, Relling MV, Downing JR. Acute lymphoblastic leukemia. N Engl J Med. 2004 Apr 8;350(15):1535-48. აბსტრაქტი
2. Hoelzer D, Gökbuget N, Ottmann O, et al. Acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2002 Jan;(1):162-92.სრული ტექსტი აბსტრაქტი
3. Jabbour EJ, Faderl S, Kantarjian HM. Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2005 Nov;80(11):1517-27. აბსტრაქტი
4. Bene MC, Castoldi G, Knapp W, et al. Proposals for the immunological classification of acute leukaemias. European Group for the Immunological Characterization of Leukemias (EGIL). Leukemia. 1995 Oct;9(10):1783-6. აბსტრაქტი
5. Terwilliger T, Abdul-Hay M. Acute lymphoblastic leukemia: a comprehensive review and 2017 update. Blood Cancer J. 2017 Jun 30;7(6):e577.სრული ტექსტი აბსტრაქტი
6. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia. 2022 Jul;36(7):1720-48.სრული ტექსტი აბსტრაქტი
7. Arber DA, Orazi A, Hasserjian RP, et al. International consensus classification of myeloid neoplasms and acute leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022 Sep 15;140(11):1200-8.სრული ტექსტი აბსტრაქტი
8. Haferlach T, Bacher U, Kern W, et al. Diagnostic pathways in acute leukemias: a proposal for a multimodal approach. Ann Hematol. 2007 May;86(5):311-27. აბსტრაქტი
9. National Cancer Institute. Surveillance, epidemiology, and end Results (SEER) Program. Cancer stat facts: leukemia - acute lymphocytic leukemia (ALL). 2024 [internet publication].სრული ტექსტი
10. National Cancer Institute. SEER Explorer: All cancer sites combined. Recent trends in SEER age-adjusted incidence rates, 2000-2020. 2023 [internet publication].სრული ტექსტი
11. Greaves MF, Maia AT, Wiemels JL, et al. Leukemia in twins: lessons in natural history. Blood. 2003 Oct 1;102(7):2321-33. აბსტრაქტი
12. De Keersmaecker K, Marynen P, Cools J. Genetic insights in the pathogenesis of T-cell acute lymphoblastic leukemia. Haematologica. 2005 Aug;90(8):1116-27. აბსტრაქტი
13. Machatschek JN, Schrauder A, Helm F, et al. Acute lymphoblastic leukemia and Klinefelter syndrome in children: two cases and review of the literature. Pediatr Hematol Oncol. 2004 Oct-Nov;21(7):621-6. აბსტრაქტი
14. Bloom M, Maciaszek JL, Clark ME, et al. Recent advances in genetic predisposition to pediatric acute lymphoblastic leukemia. Expert Rev Hematol. 2020 Jan;13(1):55-70. აბსტრაქტი
15. Kratz CP, Stanulla M, Cavé H. Genetic predisposition to acute lymphoblastic leukemia: Overview on behalf of the I-BFM ALL Host Genetic Variation Working Group. Eur J Med Genet. 2016 Mar;59(3):111-5. აბსტრაქტი
16. Moriyama T, Metzger ML, Wu G, et al. Germline genetic variation in ETV6 and risk of childhood acute lymphoblastic leukaemia: a systematic genetic study. Lancet Oncol. 2015 Dec;16(16):1659-66.სრული ტექსტი აბსტრაქტი
17. Pui CH, Nichols KE, Yang JJ. Somatic and germline genomics in paediatric acute lymphoblastic leukaemia. Nat Rev Clin Oncol. 2019 Apr;16(4):227-40. აბსტრაქტი
18. Klco JM, Mullighan CG. Advances in germline predisposition to acute leukaemias and myeloid neoplasms. Nat Rev Cancer. 2021 Feb;21(2):122-37.სრული ტექსტი აბსტრაქტი
19. Snyder DS, Stein AS, O'Donnell MR, et al, Philadelphia chromosome-positive acute lymphoblastic leukemia secondary to chemoradiotherapy for Ewing sarcoma. Report of two cases and concise review of the literature. Am J Hematol. 2005 Jan;78(1):74-8. აბსტრაქტი
20. Petridou E, Ntouvelis E, Dessypris N, et al. Maternal diet and acute lymphoblastic leukemia in young children. Cancer Epidemiol Biomarkers Prev. 2005 Aug;14(8):1935-9.სრული ტექსტი აბსტრაქტი
21. Abiri B, Kelishadi R, Sadeghi H, et al. Effects of maternal diet during pregnancy on the risk of childhood acute lymphoblastic leukemia: a systematic review. Nutr Cancer. 2016 Oct;68(7):1065-72. აბსტრაქტი
22. Dessypris N, Karalexi MA, Ntouvelis E, et al. Association of maternal and index child's diet with subsequent leukemia risk: a systematic review and meta analysis. Cancer Epidemiol. 2017 Apr;47:64-75. აბსტრაქტი
23. Kwan ML, Jensen CD, Block G, et al. Maternal diet and risk of childhood acute lymphoblastic leukemia. Public Health Rep. 2009 Jul-Aug;124(4):503-14.სრული ტექსტი აბსტრაქტი
24. Koppen IJ, Hermans FJ, Kaspers GJ. Folate related gene polymorphisms and susceptibility to develop childhood acute lymphoblastic leukaemia. Br J Haematol. 2010 Jan;148(1):3-14. აბსტრაქტი
25. Gast A, Bermejo JL, Flohr T, et al. Folate metabolic gene polymorphisms and childhood acute lymphoblastic leukemia: a case-control study. Leukemia. 2007 Feb;21(2):320-5. აბსტრაქტი
26. de Jonge R, Tissing WJ, Hooijberg JH, et al. Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia. Blood. 2009 Mar 5;113(10):2284-9.სრული ტექსტი აბსტრაქტი
27. Lupo PJ, Nousome D, Kamdar KY, et al. A case-parent triad assessment of folate metabolic genes and the risk of childhood acute lymphoblastic leukemia. Cancer Causes Control. 2012 Nov;23(11):1797-803.სრული ტექსტი აბსტრაქტი
28. Cox CV, Blair A. A primitive cell origin for B-cell precursor ALL? Stem Cell Rev. 2005;1(3):189-96. აბსტრაქტი
29. Randolph TR. Advances in acute lymphoblastic leukemia. Clin Lab Sci. 2004 Fall;17(4):235-45. აბსტრაქტი
30. Hoffman R, Shattil SJ, Furie B, et al. Hematology: basic principles and practice. Vol 1. 4th ed. Orlando, FL: Churchill Livingstone / W.B. Saunders; 2005.
31. D'Achille P, Seymour JF, Campbell LJ. Translocation (14;18)(q32;q21) in acute lymphoblastic leukemia: a study of 12 cases and review of the literature. Cancer Genet Cytogenet. 2006 Nov;171(1):52-6. აბსტრაქტი
32. Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2003 Oct 1;98(7):1337-54. აბსტრაქტი
33. Iacobucci I, Mullighan CG. Genetic Basis of Acute Lymphoblastic Leukemia. J Clin Oncol. 2017 Mar 20;35(9):975-83. აბსტრაქტი
34. Owattanapanich W, Rujirachun P, Ungprasert P, et al. Prevalence and clinical outcome of Philadelphia-like acute lymphoblastic leukemia: systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk. 2020 Jan;20(1):e22-9.სრული ტექსტი აბსტრაქტი
35. Tanasi I, Ba I, Sirvent N, et al. Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements. Blood. 2019 Oct 17;134(16):1351-5.სრული ტექსტი აბსტრაქტი
36. Yokota T, Kanakura Y. Genetic abnormalities associated with acute lymphoblastic leukemia. Cancer Sci. 2016 Jun;107(6):721-5.სრული ტექსტი აბსტრაქტი
37. Kox C, Zimmermann M, Stanulla M, et al. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-ALL patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia. 2010 Dec;24(12):2005-13.სრული ტექსტი აბსტრაქტი
38. Mullighan CG, Zhang J, Kasper LH, et al. CREBBP mutations in relapsed acute lymphoblastic leukaemia. Nature. 2011 Mar 10;471(7337):235-9.სრული ტექსტი აბსტრაქტი
39. Iacobucci I, Lonetti A, Paoloni F, et al. The PAX5 gene is frequently rearranged in BCR-ABL1-positive acute lymphoblastic leukemia but is not associated with outcome. A report on behalf of the GIMEMA Acute Leukemia Working Party. Haematologica. 2010 Oct;95(10):1683-90.სრული ტექსტი აბსტრაქტი
40. Coyaud E, Struski S, Prade N, et al. Wide diversity of PAX5 alterations in B-ALL: a Groupe Francophone de Cytogenetique Hematologique study. Blood. 2010 Apr 15;115(15):3089-97.სრული ტექსტი აბსტრაქტი
41. Van Vlierberghe P, Palomero T, Khiabanian H, et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet. 2010 Apr;42(4):338-42.სრული ტექსტი აბსტრაქტი
42. Karrman K, Castor A, Behrendtz M, et al. Deep sequencing and SNP array analyses of pediatric T-cell acute lymphoblastic leukemia reveal NOTCH1 mutations in minor subclones and a high incidence of uniparental isodisomies affecting CDKN2A. J Hematol Oncol. 2015 Apr 24;8:42.სრული ტექსტი აბსტრაქტი
43. Dhanyamraju PK, Iyer S, Smink G, et al. Transcriptional regulation of genes by Ikaros tumor suppressor in acute lymphoblastic leukemia. Int J Mol Sci. 2020 Feb 18;21(4):1377.სრული ტექსტი აბსტრაქტი
44. Della Ragione F, Mercurio C, Iolascon A. Cell cycle regulation and human leukemias: the role of p16INK4 gene inactivation in the development of human acute lymphoblastic leukemia. Haematologica. 1995 Nov-Dec;80(6):557-68. აბსტრაქტი
45. Kuiper RP, Waanders E, van der Velden VH, et al. IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL. Leukemia. 2010 Jul;24(7):1258-64. აბსტრაქტი
46. Stanulla M, Dagdan E, Zaliova M, et al. IKZF1(plus) defines a new minimal residual disease-dependent very-poor prognostic profile in pediatric B-cell precursor acute lymphoblastic leukemia. J Clin Oncol. 2018 Apr 20;36(12):1240-9.სრული ტექსტი აბსტრაქტი
47. Gallagher DJ, Phillips DJ, Heinrich SD. Orthopedic manifestations of acute pediatric leukemia. Orthop Clin North Am. 1996 Jul;27(3):635-44. აბსტრაქტი
48. Abeloff MD, Armitage J, Niederhuber JE, et al. Clinical oncology. 3rd ed. Vol 1. Philadelphia, PA: Churchill Livingstone; 2004:3232.
49. Nguyen HTK, Terao MA, Green DM, et al. Testicular involvement of acute lymphoblastic leukemia in children and adolescents: diagnosis, biology, and management. Cancer. 2021 Sep 1;127(17):3067-81.სრული ტექსტი აბსტრაქტი
50. Reman O, Pigneux A, Huguet F, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis and/or at first relapse: results from the GET-LALA group. Leuk Res. 2008 Nov;32(11):1741-50. აბსტრაქტი
51. Lazarus HM, Richards SM, Chopra R, et al. Central nervous system involvement in adult acute lymphoblastic leukemia at diagnosis: results from the international ALL trial MRC UKALL XII/ECOG E2993. Blood. 2006 Jul 15;108(2):465-72.სრული ტექსტი აბსტრაქტი
52. Pui CH. Central nervous system disease in acute lymphoblastic leukemia: prophylaxis and treatment. Hematology Am Soc Hematol Educ Program. 2006 Jan;(1):142-6.სრული ტექსტი აბსტრაქტი
53. Lamanna N, Weiss M. Treatment options for newly diagnosed patients with adult acute lymphoblastic leukemia. Curr Hematol Rep. 2004 Jan;3(1):40-6. აბსტრაქტი
54. Richards S, Pui CH, Gayon P, et al. Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013 Feb;60(2):185-95.სრული ტექსტი აბსტრაქტი
55. Frishman-Levy L, Izraeli S. Advances in understanding the pathogenesis of CNS acute lymphoblastic leukaemia and potential for therapy. Br J Haematol. 2017 Jan;176(2):157-67.სრული ტექსტი აბსტრაქტი
56. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prevention and treatment of cancer-related infections [internet publication].სრული ტექსტი
57. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: acute lymphoblastic leukemia [internet publication].სრული ტექსტი
58. de Haas V, Ismaila N, Advani A, et al. Initial diagnostic work-up of acute leukemia: ASCO clinical practice guideline endorsement of the College of American Pathologists and American Society of Hematology guideline. J Clin Oncol. 2019 Jan 20;37(3):239-53.სრული ტექსტი აბსტრაქტი
59. Hoelzer D, Bassan R, Dombret H, et al. Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016 Sep;27(suppl 5):v69-82.სრული ტექსტი აბსტრაქტი
60. Lavi R, Yarnitsky D, Rowe JM, et al. Standard vs atraumatic Whitacre needle for diagnostic lumbar puncture: a randomized trial. Neurology. 2006 Oct 24;67(8):1492-4. აბსტრაქტი
61. Arendt K, Demaerschalk BM, Wingerchuk DM, Camann W. Atraumatic lumbar puncture needles: after all these years, are we still missing the point? Neurologist. 2009 Jan;15(1):17-20. აბსტრაქტი
62. Nath S, Koziarz A, Badhiwala JH, et al. Atraumatic versus conventional lumbar puncture needles: a systematic review and meta-analysis. Lancet. 2018 Mar 24;391(10126):1197-204. აბსტრაქტი
63. Rochwerg B, Almenawer SA, Siemieniuk RAC, et al. Atraumatic (pencil-point) versus conventional needles for lumbar puncture: a clinical practice guideline. BMJ. 2018 May 22;361:k1920.სრული ტექსტი აბსტრაქტი
64. Ahmed SV, Jayawarna C, Jude E. Post lumbar puncture headache: diagnosis and management. Postgrad Med J. 2006 Nov;82(973):713-6.სრული ტექსტი აბსტრაქტი
65. Arevalo-Rodriguez I, Ciapponi A, Roqué i Figuls M, et al. Posture and fluids for preventing post-dural puncture headache. Cochrane Database Syst Rev. 2016 Mar 7;(3):CD009199.სრული ტექსტი აბსტრაქტი
66. Del Principe MI, Buzzatti E, Piciocchi A, et al. Clinical significance of occult central nervous system disease in adult acute lymphoblastic leukemia. A multicenter report from the Campus ALL Network. Haematologica. 2021 Jan 1;106(1):39-45.სრული ტექსტი აბსტრაქტი
67. Garcia KA, Cherian S, Stevenson PA, et al. Cerebrospinal fluid flow cytometry and risk of central nervous system relapse after hyperCVAD in adults with acute lymphoblastic leukemia. Cancer. 2022 Apr 1;128(7):1411-7. აბსტრაქტი
68. Winick N, Devidas M, Chen S, et al. Impact of initial CSF findings on outcome among patients with National Cancer Institute standard- and high-risk B-cell acute lymphoblastic leukemia: a report from the children's oncology group. J Clin Oncol. 2017 Aug 1;35(22):2527-34.სრული ტექსტი აბსტრაქტი
69. Kopmar NE, Cassaday RD. How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia. Blood. 2023 Mar 23;141(12):1379-88.სრული ტექსტი აბსტრაქტი
70. Relling MV, Schwab M, Whirl-Carrillo M, et al. Clinical pharmacogenetics implementation consortium guideline for thiopurine dosing based on TPMT and NUDT15 genotypes: 2018 update. Clin Pharmacol Ther. 2019 May;105(5):1095-105.სრული ტექსტი აბსტრაქტი
71. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: myeloid/lymphoid neoplasms with eosinophilia and tyrosine kinase gene fusions [internet publication].სრული ტექსტი
72. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia. 2022 Jul;36(7):1703-19.სრული ტექსტი აბსტრაქტი
73. Bassan R, Hoelzer D. Modern therapy of acute lymphoblastic leukemia. J Clin Oncol. 2011 Feb 10;29(5):532-43. აბსტრაქტი
74. Hunger SP, Loh ML, Whitlock JA, et al. Children's Oncology Group's 2013 blueprint for research: acute lymphoblastic leukemia. Pediatr Blood Cancer. 2013 Jun;60(6):957-63. აბსტრაქტი
75. Rowe JM, Buck G, Burnett AK, et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. Blood. 2005 Dec 1;106(12):3760-7.სრული ტექსტი აბსტრაქტი
76. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008 Feb 15;111(4):1827-33.სრული ტექსტი აბსტრაქტი
77. Jeha S, Behm F, Pei D, et al. Prognostic significance of CD20 expression in childhood B-cell precursor acute lymphoblastic leukemia. Blood. 2006 Nov 15;108(10):3302-4.სრული ტექსტი აბსტრაქტი
78. Dekker SE, Rea D, Cayuela JM, et al. Using measurable residual disease to optimize management of AML, ALL, and chronic myeloid leukemia. Am Soc Clin Oncol Educ Book. 2023 Jun;43:e390010.სრული ტექსტი აბსტრაქტი
79. Krishnan S, Wade R, Moorman AV, et al. Temporal changes in the incidence and pattern of central nervous system relapses in children with acute lymphoblastic leukaemia treated on four consecutive Medical Research Council trials, 1985-2001. Leukemia. 2010 Feb;24(2):450-9.სრული ტექსტი აბსტრაქტი
80. Laningham FH, Kun LE, Reddick WE, et al. Childhood central nervous system leukemia: historical perspectives, current therapy, and acute neurological sequelae. Neuroradiology. 2007 Nov;49(11):873-88.სრული ტექსტი აბსტრაქტი
81. Pui CH, Howard SC. Current management and challenges of malignant disease in the CNS in paediatric leukaemia. Lancet Oncol. 2008 Mar;9(3):257-68. აბსტრაქტი
82. Thomas X, Boiron JM, Huguet F, et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. J Clin Oncol. 2004 Oct 15;22(20):4075-86.სრული ტექსტი აბსტრაქტი
83. Petersdorf SH, Kopecky KJ, Head DR, et al. Comparison of the L10M consolidation regimen to an alternative regimen including escalating methotrexate/L-asparaginase for adult acute lymphoblastic leukemia: a Southwest Oncology Group Study. Leukemia. 2001 Feb;15(2):208-16. აბსტრაქტი
84. Kantarjian HM, O'Brien S, Smith TL, et al. Results of treatment with hyper-CVAD, a dose-intensive regimen, in adult acute lymphocytic leukemia. J Clin Oncol. 2000 Feb;18(3):547-61. აბსტრაქტი
85. Hoelzer D, Thiel E, Löffler H, et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood. 1988 Jan;71(1):123-31.სრული ტექსტი აბსტრაქტი
86. Surapaneni UR, Cortes JE, Thomas D, et al. Central nervous system relapse in adults with acute lymphoblastic leukemia. Cancer. 2002 Feb 1;94(3):773-9.სრული ტექსტი აბსტრაქტი
87. Pui CH, Evans WH. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006 Jan 12;354(2):166-78. აბსტრაქტი
88. Schrappe M, Reiter A, Zimmermann M, et al. Long-term results of four consecutive trials in childhood ALL performed by the ALL-BFM study group from 1981 to 1995. Berlin-Frankfurt-Münster. Leukemia. 2000 Dec;14(12):2205-22. აბსტრაქტი
89. Stock W, Luger SM, Advani AS, et al. A pediatric regimen for older adolescents and young adults with acute lymphoblastic leukemia: results of CALGB 10403. Blood. 2019 Apr 4;133(14):1548-59.სრული ტექსტი აბსტრაქტი
90. Morita K, Jain N, Kantarjian H, et al. Outcome of T-cell acute lymphoblastic leukemia/lymphoma: focus on near-ETP phenotype and differential impact of nelarabine. Am J Hematol. 2021 May 1;96(5):589-98.სრული ტექსტი აბსტრაქტი
91. Heo YA, Syed YY, Keam SJ. Pegaspargase: a review in acute lymphoblastic leukaemia. Drugs. 2019 May;79(7):767-77.სრული ტექსტი აბსტრაქტი
92. Place AE, Stevenson KE, Vrooman LM, et al. Intravenous pegylated asparaginase versus intramuscular native Escherichia coli L-asparaginase in newly diagnosed childhood acute lymphoblastic leukaemia (DFCI 05-001): a randomised, open-label phase 3 trial. Lancet Oncol. 2015 Dec;16(16):1677-90. აბსტრაქტი
93. Vrooman LM, Blonquist TM, Supko JG, et al. Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia/lymphoma: results of DFCI 11-001. Paper presented at: 2019 ASCO Annual Meeting. Jun 1-3 2019. Chicago, IL. J Clin Oncol 2019 May 20;37 (15 suppl):10006.სრული ტექსტი
94. Vrooman LM, Blonquist TM, Stevenson KE, et al. Efficacy and toxicity of pegaspargase and calaspargase pegol in childhood acute lymphoblastic leukemia: results of DFCI 11-001. J Clin Oncol. 2021 Nov 1;39(31):3496-505.სრული ტექსტი აბსტრაქტი
95. Maese L, Loh ML, Choi MR, et al. Recombinant Erwinia asparaginase (JZP458) in acute lymphoblastic leukemia: results from the phase 2/3 AALL1931 study. Blood. 2023 Feb 16;141(7):704-12.სრული ტექსტი აბსტრაქტი
96. Kantarjian H, Thomas D, O'Brien S, et al. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia. Cancer. 2004 Dec 15;101(12):2788-801.სრული ტექსტი აბსტრაქტი
97. Sive JI, Buck G, Fielding A, et al. Outcomes in older adults with acute lymphoblastic leukaemia (ALL): results from the international MRC UKALL XII/ECOG2993 trial. Br J Haematol. 2012 May;157(4):463-71.სრული ტექსტი აბსტრაქტი
98. Pulte D, Jansen L, Gondos A, et al. Survival of adults with acute lymphoblastic leukemia in Germany and the United States. PLoS One. 2014 Jan 27;9(1):e85554.სრული ტექსტი აბსტრაქტი
99. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. Blood. 1995 Apr 15;85(8):2025-37. აბსტრაქტი
100. Rea D, Legros L, Raffoux E, et al; Intergroupe Français des Leucémies Myéloïdes Chronique; Group for Research in Adult Acute Lymphoblastic Leukemia. High-dose imatinib mesylate combined with vincristine and dexamethasone (DIV regimen) as induction therapy in patients with resistant Philadelphia-positive acute lymphoblastic leukemia and lymphoid blast crisis of chronic myeloid leukemia. Leukemia. 2006 Mar;20(3):400-3. აბსტრაქტი
101. Schultz KR, Bowman WP, Aledo A, et al. Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a Children's Oncology Group study. J Clin Oncol. 2009 Nov 1;27(31):5175-81.სრული ტექსტი აბსტრაქტი
102. Schultz KR, Carroll A, Heerema NA, et al; Children’s Oncology Group. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031. Leukemia. 2014 Jul;28(7):1467-71. აბსტრაქტი
103. Foà R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011 Dec 15;118(25):6521-8.სრული ტექსტი აბსტრაქტი
104. Kim DY, Joo YD, Lim SN, et al. Nilotinib combined with multiagent chemotherapy for newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Blood. 2015 Aug 6;126(6):746-56.სრული ტექსტი აბსტრაქტი
105. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004 Jun 15;103(12):4396-407.სრული ტექსტი აბსტრაქტი
106. Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010 Sep 23;116(12):2070-7.სრული ტექსტი აბსტრაქტი
107. Benjamini O, Dumlao TL, Kantarjian H, et al. Phase II trial of hyperCVAD and dasatinib in patients with relapsed Philadelphia chromosome positive acute lymphoblastic leukemia or blast phase chronic myeloid leukemia. Am J Hematol. 2014 Mar;89(3):282-7.სრული ტექსტი აბსტრაქტი
108. Jabbour E, Kantarjian H, Ravandi F, et al. Combination of hyper-CVAD with ponatinib as first-line therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia: a single-centre, phase 2 study. Lancet Oncol. 2015 Nov;16(15):1547-55.სრული ტექსტი აბსტრაქტი
109. Maury S, Chevret S, Thomas X, et al. Rituximab in B-lineage adult acute lymphoblastic leukemia. N Engl J Med. 2016 Sep 15;375(11):1044-53. აბსტრაქტი
110. Jabbour E, DerSarkissian M, Duh MS, et al. Efficacy of ponatinib versus earlier generation tyrosine kinase inhibitors for front-line treatment of newly diagnosed Philadelphia-positive acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk. 2018 Apr;18(4):257-65. აბსტრაქტი
111. Aldoss I, Ribera J-M, Kantarjian H, et al. Ponatinib versus imatinib in patients with newly diagnosed Ph+ ALL: subgroup analysis of the phase 3 Phallcon study. Blood. 2023 Nov 2;142(suppl 1):2871.
112. DeAngelo DJ, Stevenson KE, Dahlberg SE, et al. Long-term outcome of a pediatric-inspired regimen used for adults aged 18-50 years with newly diagnosed acute lymphoblastic leukemia. Leukemia. 2015 Mar;29(3):526-34.სრული ტექსტი აბსტრაქტი
113. Giammarco S, Chiusolo P, Piccirillo N, et al. Hyperleukocytosis and leukostasis: management of a medical emergency. Expert Rev Hematol. 2017 Feb;10(2):147-54. აბსტრაქტი
114. Macaron W, Sargsyan Z, Short NJ. Hyperleukocytosis and leukostasis in acute and chronic leukemias. Leuk Lymphoma. 2022 Aug;63(8):1780-91. აბსტრაქტი
115. Giebel S, Marks DI, Boissel N, et al. Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2019 Jun;54(6):798-809.სრული ტექსტი აბსტრაქტი
116. Huguet F, Chevret S, Leguay T, et al. Intensified therapy of acute lymphoblastic leukemia in adults: report of the randomized GRAALL-2005 clinical trial. J Clin Oncol. 2018 Aug 20;36(24):2514-23.სრული ტექსტი აბსტრაქტი
117. Stelljes M, Marks DI. Chapter 71: acute lymphoblastic leukemia in adults. 71.5: prognostic factors used to indicate allo-HSCT in CR1. In: Carreras E, Dufour C, Mohty M, et al, eds. The EBMT handbook: hematopoietic stem cell transplantation and cellular therapies. 7th ed. Cham, Switzerland: Springer; 2019.სრული ტექსტი
118. DeFilipp Z, Advani AS, Bachanova V, et al. Hematopoietic cell transplantation in the treatment of adult acute lymphoblastic leukemia: updated 2019 evidence-based review from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2019 Nov;25(11):2113-23.სრული ტექსტი აბსტრაქტი
119. Gökbuget N, Dombret H, Bonifacio M, et al. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia. Blood. 2018 Apr 5;131(14):1522-31.სრული ტექსტი აბსტრაქტი
120. Hoelzer D, Ludwig WD, Thiel E, et al. Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood. 1996 Jan 15;87(2):495-508. აბსტრაქტი
121. Teachey DT, Hunger SP, Loh ML. Optimizing therapy in the modern age: differences in length of maintenance therapy in acute lymphoblastic leukemia. Blood. 2021 Jan 14;137(2):168-77.სრული ტექსტი აბსტრაქტი
122. Samra B, Kantarjian HM, Sasaki K, et al. Discontinuation of maintenance tyrosine kinase inhibitors in Philadelphia chromosome-positive acute lymphoblastic leukemia outside of transplant. Acta Haematol. 2021;144(3):285-92. აბსტრაქტი
123. Sancho JM, Ribera JM, Oriol A, et al. Central nervous system recurrence in adult patients with acute lymphoblastic leukemia: frequency and prognosis in 467 patients without cranial irradiation for prophylaxis. Cancer. 2006 Jun 15;106(12):2540-6.სრული ტექსტი აბსტრაქტი
124. Pinnix CC, Yahalom J, Specht L, et al. Radiation in central nervous system leukemia: guidelines from the International Lymphoma Radiation Oncology Group. Int J Radiat Oncol Biol Phys. 2018 Sep 1;102(1):53-8.სრული ტექსტი აბსტრაქტი
125. Ghobadi A, Slade M, Kantarjian H, et al. The role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis. Blood. 2022 Nov 17;140(20):2101-12.სრული ტექსტი აბსტრაქტი
126. Ram R, Gafter-Gvili A, Vidal L, et al. Management of adult patients with acute lymphoblastic leukemia in first complete remission: systematic review and meta-analysis. Cancer. 2010 Jul 15;116(14):3447-57.სრული ტექსტი აბსტრაქტი
127. Shah S, Martin A, Turner M, et al. A systematic review of outcomes after stem cell transplantation in acute lymphoblastic leukemia with or without measurable residual disease. Leuk Lymphoma. 2020 May;61(5):1052-62. აბსტრაქტი
128. Pavlů J, Labopin M, Niittyvuopio R, et al. Measurable residual disease at myeloablative allogeneic transplantation in adults with acute lymphoblastic leukemia: a retrospective registry study on 2780 patients from the acute leukemia working party of the EBMT. J Hematol Oncol. 2019 Oct 23;12(1):108.სრული ტექსტი აბსტრაქტი
129. Holtick U, Albrecht M, Chemnitz JM, et al. Bone marrow versus peripheral blood allogeneic haematopoietic stem cell transplantation for haematological malignancies in adults. Cochrane Database Syst Rev. 2014 Apr 20;(4):CD010189.სრული ტექსტი აბსტრაქტი
130. Park M, Lee YH. Cord blood transplantation for the treatment of acute leukemia. Chin Med J (Engl). 2013 Feb;126(4):761-7.სრული ტექსტი აბსტრაქტი
131. Zhang H, Chen J, Que W. A meta-analysis of unrelated donor umbilical cord blood transplantation versus unrelated donor bone marrow transplantation in acute leukemia patients. Biol Blood Marrow Transplant. 2012 Aug;18(8):1164-73.სრული ტექსტი აბსტრაქტი
132. Kröger N, Solano C, Wolschke C, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016 Jan 7;374(1):43-53.სრული ტექსტი აბსტრაქტი
133. Giebel S, Czyz A, Ottmann O, et al. Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2016 Oct;122(19):2941-51.სრული ტექსტი აბსტრაქტი
134. Warraich Z, Tenneti P, Thai T, et al. Relapse prevention with tyrosine kinase inhibitors after allogeneic transplantation for Philadelphia chromosome-positive acute lymphoblast leukemia: a systematic review. Biol Blood Marrow Transplant. 2020 Mar;26(3):e55-64.სრული ტექსტი აბსტრაქტი
135. Thomas DA, Kantarjian H, Smith TL, et al. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999 Oct 1;86(7):1216-30. აბსტრაქტი
136. Kantarjian HM, Thomas D, Ravandi F, et al. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer. 2010 Dec 15;116(24):5568-74.სრული ტექსტი აბსტრაქტი
137. Tavernier E, Boiron JM, Huguet F, et al; GET-LALA Group; Swiss Group for Clinical Cancer Research SAKK; Australasian Leukaemia and Lymphoma Group. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007 Sep;21(9):1907-14. აბსტრაქტი
138. Oriol A, Vives S, Hernández-Rivas JM, et al; Programa Español de Tratamiento en Hematologia Group. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. 2010 Apr;95(4):589-96.სრული ტექსტი აბსტრაქტი
139. Kimble EL, Cassaday RD. Antibody and cellular immunotherapies for acute lymphoblastic leukemia in adults. Leuk Lymphoma. 2021 Dec;62(14):3333-47. აბსტრაქტი
140. Kantarjian H, Stein A, Gökbuget N, et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017 Mar 2;376(9):836-47.სრული ტექსტი აბსტრაქტი
141. Brown PA, Ji L, Xu X, et al. Effect of postreinduction therapy consolidation with blinatumomab vs chemotherapy on disease-free survival in children, adolescents, and young adults with first relapse of B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021 Mar 2;325(9):833-42.სრული ტექსტი აბსტრაქტი
142. Locatelli F, Zugmaier G, Rizzari C, et al. Effect of blinatumomab vs chemotherapy on event-free survival among children with high-risk first-relapse B-cell acute lymphoblastic leukemia: a randomized clinical trial. JAMA. 2021 Mar 2;325(9):843-54.სრული ტექსტი აბსტრაქტი
143. Kantarjian HM, DeAngelo DJ, Stelljes M, et al. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016 Aug 25;375(8):740-53.სრული ტექსტი აბსტრაქტი
144. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018 Feb 1;378(5):439-48.სრული ტექსტი აბსტრაქტი
145. Shah BD, Ghobadi A, Oluwole OO, et al. KTE-X19 for relapsed or refractory adult B-cell acute lymphoblastic leukaemia: phase 2 results of the single-arm, open-label, multicentre ZUMA-3 study. Lancet. 2021 Aug 7;398(10299):491-502. აბსტრაქტი
146. Kantarjian H, Thomas D, Jorgensen J, et al. Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 1;119(15):2728-36.სრული ტექსტი აბსტრაქტი
147. Kantarjian HM, DeAngelo DJ, Advani AS, et al. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017 Aug;4(8):e387-98. აბსტრაქტი
148. Grupp SA, Kalos M, Barrett D, et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med. 2013 Apr 18;368(16):1509-18.სრული ტექსტი აბსტრაქტი
149. Maude SL, Frey N, Shaw PA, et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014 Oct 16;371(16):1507-17.სრული ტექსტი აბსტრაქტი
150. Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of immune-related adverse events in patients treated with chimeric antigen receptor T-Cell therapy: ASCO Guideline. J Clin Oncol. 2021 Dec 10;39(35):3978-92.სრული ტექსტი აბსტრაქტი
151. Food and Drug Administration. FDA requires boxed warning for T cell malignancies following treatment with BCMA-directed or CD19-directed autologous chimeric antigen receptor (CAR) T cell immunotherapies. Apr 2024 [internet publication].სრული ტექსტი
152. Segal BH, Freifeld AG. Antibacterial prophylaxis in patients with neutropenia. J Natl Compr Canc Netw. 2007 Feb;5(2):235-42. აბსტრაქტი
153. Robenshtok E, Gafter-Gvili A, Goldberg E, et al. Antifungal prophylaxis in cancer patients after chemotherapy or haematopoietic stem-cell transplantation: systematic review and meta-analysis. J Clin Oncol. 2007 Dec 1;25(34):5471-89. აბსტრაქტი
154. Taplitz RA, Kennedy EB, Bow EJ, et al. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update. J Clin Oncol. 2018 Oct 20;36(30):3043-54.სრული ტექსტი აბსტრაქტი
155. Lehrnbecher T, Fisher BT, Phillips B, et al. Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients. J Clin Oncol. 2020 Sep 20;38(27):3205-16.სრული ტექსტი აბსტრაქტი
156. Kuderer NM, Dale DC, Crawford J, et al. Mortality, morbidity, and cost associated with febrile neutropenia in adult cancer patients. Cancer. 2006 May 15;106(10):2258-66.სრული ტექსტი აბსტრაქტი
157. National Comprehensive Cancer Network. NCCN practice guidelines in oncology: hematopoietic growth factors [internet publication].სრული ტექსტი
158. Crighton GL, Estcourt LJ, Wood EM, et al. A therapeutic-only versus prophylactic platelet transfusion strategy for preventing bleeding in patients with haematological disorders after myelosuppressive chemotherapy or stem cell transplantation. Cochrane Database Syst Rev. 2015 Sep 30;(9):CD010981.სრული ტექსტი აბსტრაქტი
159. Stanworth SJ, Estcourt LJ, Powter G, et al; TOPPS Investigators. A no-prophylaxis platelet-transfusion strategy for hematologic cancers. N Engl J Med. 2013 May 9;368(19):1771-80.სრული ტექსტი აბსტრაქტი
160. Asselin BL, Devidas M, Chen L, et al. Cardioprotection and safety of dexrazoxane in patients treated for newly diagnosed T-cell acute lymphoblastic leukemia or advanced-stage lymphoblastic non-Hodgkin lymphoma: a report of the Children's Oncology Group Randomized Trial Pediatric Oncology Group 9404. J Clin Oncol. 2016 Mar 10;34(8):854-62.სრული ტექსტი აბსტრაქტი
161. Dolmans MM, Marinescu C, Saussoy P, et al. Reimplantation of cryopreserved ovarian tissue from patients with acute lymphoblastic leukemia is potentially unsafe. Blood. 2010 Oct 21;116(16):2908-14.სრული ტექსტი აბსტრაქტი
162. Evans K, Duan J, Pritchard T, et al. OBI-3424, a novel AKR1C3-activated prodrug, exhibits potent efficacy against preclinical models of T-ALL. Clin Cancer Res. 2019 Jul 15;25(14):4493-503.სრული ტექსტი აბსტრაქტი
163. ClinicalTrials.gov. Study to test AKR1C3-activated prodrug OBI-3424 (OBI-3424) in patients with relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL). NCT04315324. Nov 2022 [internet publication].სრული ტექსტი
164. ClinicalTrials.gov. A study of revumenib in combination with chemotherapy for patients diagnosed with relapsed or refractory leukemia. Oct 2023 [internet publication].სრული ტექსტი
165. Foà R, Bassan R, Vitale A, et al; GIMEMA Investigators. Dasatinib-blinatumomab for Ph-positive acute lymphoblastic leukemia in adults. N Engl J Med. 2020 Oct 22;383(17):1613-23.სრული ტექსტი აბსტრაქტი
166. Jabbour E, Short NJ, Jain N, et al. Hyper-CVAD and sequential blinatumomab for newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: a single-arm, single-centre, phase 2 trial. Lancet Haematol. 2022 Dec;9(12):e878-85. აბსტრაქტი
167. Jain N, Maiti A, Ravandi F, et al. Inotuzumab ozogamicin with bosutinib for relapsed or refractory Philadelphia chromosome positive acute lymphoblastic leukemia or lymphoid blast phase of chronic myeloid leukemia. Am J Hematol. 2021 Aug 1;96(8):1000-7.სრული ტექსტი აბსტრაქტი
168. Jabbour E, Short NJ, Senapati J, et al. Mini-hyper-CVD plus inotuzumab ozogamicin, with or without blinatumomab, in the subgroup of older patients with newly diagnosed Philadelphia chromosome-negative B-cell acute lymphocytic leukaemia: long-term results of an open-label phase 2 trial. Lancet Haematol. 2023 Jun;10(6):e433-44. აბსტრაქტი
169. Thomas X, Le QH. Current therapeutic strategies in acute lymphoblastic leukemia in the adult. Bull Cancer. 2003 Oct;90(10):833-50. აბსტრაქტი
170. Thomas X, Le QH. Prognostic factors in adult acute lymphoblastic leukemia. Hematology. 2003 Aug;8(4):233-42. აბსტრაქტი
171. Pui CH, Carroll WL, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemias: an update. J Clin Oncol. 2011 Feb 10;29(5):551-65. აბსტრაქტი
172. Rowe JM. Prognostic factors in adult acute lymphoblastic leukaemia. Br J Haematol. 2010 Aug;150(4):389-405. აბსტრაქტი
173. Smith M, Arthur D, Camitta B, et al. Uniform approach to risk classification and treatment assignment for children with acute lymphoblastic leukemia. J Clin Oncol. 1996 Jan;14(1):18-24. აბსტრაქტი
174. Teachey DT, Hunger SP. Predicting relapse risk in childhood acute lymphoblastic leukaemia. Br J Haematol. 2013 Sep;162(5):606-20.სრული ტექსტი აბსტრაქტი
175. Kebriaei P, Poon LM. The role of allogeneic hematopoietic stem cell transplantation in the therapy of patients with acute lymphoblastic leukemia. Curr Hematol Malig Rep. 2012 Jun;7(2):144-52. აბსტრაქტი
176. Cassaday RD, Alan Potts D Jr, Stevenson PA, et al. Evaluation of allogeneic transplantation in first or later minimal residual disease - negative remission following adult-inspired therapy for acute lymphoblastic leukemia. Leuk Lymphoma. 2016 Sep;57(9):2109-18.სრული ტექსტი აბსტრაქტი
177. Caruso V, Iacoviello L, Di Castelnuovo A, et al. Venous thrombotic complications in adults undergoing induction treatment for acute lymphoblastic leukaemia: results from a meta-analysis. J Thromb Haemost. 2007 Mar;5(3):621-3. აბსტრაქტი
178. Albertsen BK, Grell K, Abrahamsson J, et al. Intermittent versus continuous PEG-asparaginase to reduce asparaginase-associated toxicities: a NOPHO ALL2008 randomized study. J Clin Oncol. 2019 Jul 1;37(19):1638-46.სრული ტექსტი აბსტრაქტი
179. Liu Y, Smith CA, Panetta JC, et al. Antibodies predict pegaspargase allergic reactions and failure of rechallenge. J Clin Oncol. 2019 Aug 10;37(23):2051-61.სრული ტექსტი აბსტრაქტი
180. Rank CU, Wolthers BO, Grell K, et al. Asparaginase-associated pancreatitis in acute lymphoblastic leukemia: results from the NOPHO ALL2008 treatment of patients 1-45 years of age. J Clin Oncol. 2020 Jan 10;38(2):145-54.სრული ტექსტი აბსტრაქტი
181. Abbott LS, Deevska M, Fernandez CV, et al. The impact of prophylactic fresh-frozen plasma and cryoprecipitate on the incidence of central nervous system thrombosis and hemorrhage in children with acute lymphoblastic leukemia receiving asparaginase. Blood. 2009 Dec 10;114(25):5146-51.სრული ტექსტი აბსტრაქტი
182. Grace RF, Dahlberg SE, Neuberg D, et al. The frequency and management of asparaginase-related thrombosis in paediatric and adult patients with acute lymphoblastic leukaemia treated on Dana-Farber Cancer Institute consortium protocols. Br J Haematol. 2011 Feb;152(4):452-9.სრული ტექსტი აბსტრაქტი
183. Qureshi A, Mitchell C, Richards S, et al. Asparaginase-related venous thrombosis in UKALL 2003 - re-exposure to asparaginase is feasible and safe. Br J Haematol. 2010 May;149(3):410-3.სრული ტექსტი აბსტრაქტი
184. Stern A, Green H, Paul M, et al. Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev. 2014 Oct 1;2014(10):CD005590.სრული ტექსტი აბსტრაქტი
185. European Medicines Agency. Disabling and potentially permanent side effects lead to suspension or restrictions of quinolone and fluoroquinolone antibiotics. Mar 2019 [internet publication].სრული ტექსტი
186. Harnicar S, Adel N, Jurcic J. Modification of vincristine dosing during concomitant azole therapy in adult acute lymphoblastic leukemia patients. J Oncol Pharm Pract. 2009 Sep;15(3):175-82. აბსტრაქტი
187. Patel B, Richards SM, Rowe JM, et al. High incidence of avascular necrosis in adolescents with acute lymphoblastic leukaemia: a UKALL XII analysis. Leukaemia. 2008 Feb;22(2):308-12. აბსტრაქტი
188. Elmantaser M, Stewart G, Young D, et al. Skeletal morbidity in children receiving chemotherapy for acute lymphoblastic leukaemia. Arch Dis Child. 2010 Oct;95(10):805-9. აბსტრაქტი
189. Egbelakin A, Ferguson MJ, MacGill EA, et al. Increased risk of vincristine neurotoxicity associated with low CYP3A5 expression genotype in children with acute lymphoblastic leukemia. Pediatr Blood Cancer. 2011 Mar;56(3):361-7. აბსტრაქტი
190. Inaba H, Khan RB, Laningham FH, et al. Clinical and radiological characteristics of methotrexate-induced acute encephalopathy in pediatric patients with cancer. Ann Oncol. 2008 Jan;19(1):178-84.სრული ტექსტი აბსტრაქტი
191. Panis B, Vlaar AM, van Well GT, et al. Posterior reversible encephalopathy syndrome in paediatric leukaemia. Eur J Paediatr Neurol. 2010 Nov;14(6):539-45. აბსტრაქტი
192. Vagace JM, Caceres-Marzal C, Jimenez M, et al. Methotrexate-induced subacute neurotoxicity in a child with acute lymphoblastic leukemia carrying genetic polymorphisms related to folate homeostasis. Am J Hematol. 2011 Jan;86(1):98-101.სრული ტექსტი აბსტრაქტი
193. Zwicker JI, Wang TF, DeAngelo DJ, et al. The prevention and management of asparaginase-related venous thromboembolism in adults: guidance from the SSC on Hemostasis and Malignancy of the ISTH. J Thromb Haemost. 2020 Feb;18(2):278-84.სრული ტექსტი აბსტრაქტი
194. Chow EJ, Asselin BL, Schwartz CL, et al. Late mortality after dexrazoxane treatment: a report from the Children's Oncology Group. J Clin Oncol. 2015 Aug 20;33(24):2639-45.სრული ტექსტი აბსტრაქტი
195. de Baat EC, Mulder RL, Armenian S, et al. Dexrazoxane for preventing or reducing cardiotoxicity in adults and children with cancer receiving anthracyclines. Cochrane Database Syst Rev. 2022 Sep 27;(9):CD014638.სრული ტექსტი აბსტრაქტი
196. El-Shitany NA, Tolba OA, El-Shanshory MR, et al. Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia. J Card Fail. 2012 Aug;18(8):607-13. აბსტრაქტი
197. Tashakori Beheshti A, Mostafavi Toroghi H, Hosseini G, et al. Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: a double-blind randomized trial. Cardiology. 2016;134(1):47-53. აბსტრაქტი
198. Medicines and Healthcare products Regulatory Agency. Ponatinib (Iclusig▼): reports of posterior reversible encephalopathy syndrome. Oct 2018 [internet publication].სრული ტექსტი
199. Larson RA. Management of acute lymphoblastic leukemia in older patients. Semin Hematol. 2006 Apr;43(2):126-33. აბსტრაქტი
200. Gökbuget N, Hoelzer D. Treatment of adult acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2006 Jan;(1):133-41.სრული ტექსტი აბსტრაქტი
ამ მასალის გამოყენება ექვემდებარება ჩვენს განცხადებას